StreetInsider.com News Articles

Form 8-K TherapeuticsMD, Inc. For: Jan 15

Wed, 21 Jan 2026 06:00:00 -0500

si-local-file:///var/storage/secattach/20260121/25870497.html

Form 8-K TherapeuticsMD, Inc. For: Jan 15

Wed, 21 Jan 2026 06:00:00 -0500

si-local-file:///var/storage/secattach/20260121/25870497.html

Form 4 TherapeuticsMD, Inc. For: Dec 23 Filed by: Thompson Tommy G

Mon, 29 Dec 2025 16:24:00 -0500

si-local-file:///var/storage/secattach/20251229/25786320.html

Form 4 TherapeuticsMD, Inc. For: Dec 23 Filed by: Thompson Tommy G

Mon, 29 Dec 2025 16:24:00 -0500

si-local-file:///var/storage/secattach/20251229/25786320.html

Form 8-K TherapeuticsMD, Inc. For: Dec 15

Tue, 16 Dec 2025 16:01:00 -0500

si-local-file:///var/storage/secattach/20251216/25746846.html

Form 8-K TherapeuticsMD, Inc. For: Dec 15

Tue, 16 Dec 2025 16:01:00 -0500

si-local-file:///var/storage/secattach/20251216/25746846.html

TherapeuticsMD (TXMD) Reports Q3 EPS of $0.00

Thu, 13 Nov 2025 06:38:41 -0500

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of $0.00.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

Form 8-K TherapeuticsMD, Inc. For: Nov 12

Thu, 13 Nov 2025 06:05:00 -0500

si-local-file:///var/storage/secattach/20251113/25601483.html

Form 8-K TherapeuticsMD, Inc. For: Nov 12

Thu, 13 Nov 2025 06:05:00 -0500

si-local-file:///var/storage/secattach/20251113/25601483.html

Form 10-Q TherapeuticsMD, Inc. For: Sep 30

Wed, 12 Nov 2025 17:27:00 -0500

si-local-file:///var/storage/secattach/20251112/25599907.html

Form 10-Q TherapeuticsMD, Inc. For: Sep 30

Wed, 12 Nov 2025 17:27:00 -0500

si-local-file:///var/storage/secattach/20251112/25599907.html

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025.

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Wed, 12 Nov 2025 16:05:00 -0500

Third Quarter 2025 Financial Results

Net Income (Loss) from Continuing Operations

Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024.

License Revenues from Continuing Operations

License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third

Form 4 TherapeuticsMD, Inc. For: Nov 03 Filed by: Naughton Gail K

Wed, 05 Nov 2025 16:18:00 -0500

si-local-file:///var/storage/secattach/20251105/25562452.html

Form 4 TherapeuticsMD, Inc. For: Nov 03 Filed by: Naughton Gail K

Wed, 05 Nov 2025 16:18:00 -0500

si-local-file:///var/storage/secattach/20251105/25562452.html

Form 4 TherapeuticsMD, Inc. For: Nov 03 Filed by: Thompson Tommy G

Wed, 05 Nov 2025 16:18:00 -0500

si-local-file:///var/storage/secattach/20251105/25562470.html

Form 4 TherapeuticsMD, Inc. For: Nov 03 Filed by: Thompson Tommy G

Wed, 05 Nov 2025 16:18:00 -0500

si-local-file:///var/storage/secattach/20251105/25562470.html

Form 4 TherapeuticsMD, Inc. For: Nov 03 Filed by: Walker Marlan D

Wed, 05 Nov 2025 16:17:00 -0500

si-local-file:///var/storage/secattach/20251105/25562411.html

Form 4 TherapeuticsMD, Inc. For: Nov 03 Filed by: Walker Marlan D

Wed, 05 Nov 2025 16:17:00 -0500

si-local-file:///var/storage/secattach/20251105/25562411.html